Company / Accounts Receivable
LEXICON PHARMACEUTICALS, INC. Accounts Receivable History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.4M
FY2025
5-year range
$28.0K / $5.9M
FY2021-FY2025
Trend
-31.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 10 years, ranging from $28,000 in FY2019 to $7M in FY2016.
Based on SEC 10-K filings.
$2M in FY2025 with a 10-year CAGR of +10.1%.
Improved from $1M to $2M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +10.1%
Key checks
Key Insights
- In FY2025, accounts receivable decreased 31.4% year-over-year.
- Peak accounts receivable was recorded in FY2016.
- Lowest accounts receivable in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -31.4% |
| FY2024 | $3.5M | +243.9% |
| FY2023 | $1.0M | +3507.1% |
| FY2019 | $28.0K | -99.5% |
| FY2018 | $5.9M | +22.8% |
| FY2017 | $4.8M | -35.6% |
| FY2016 | $7.5M | +722.4% |
| FY2015 | $911.0K | -12.0% |
| FY2014 | $1.0M | +31.0% |
| FY2013 | $790.0K | -42.7% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026